<DOC>
	<DOCNO>NCT01228669</DOCNO>
	<brief_summary>This trial conduct Europe Asia . The aim clinical trial investigate safety , pharmacokinetics ( trial drug distribute body ) pharmacodynamics ( physiological effect drug body ) NNC 0172-0000-2021 administer intravenously subcutaneously healthy male subject subject haemophilia A B</brief_summary>
	<brief_title>Safety NNC 0172-0000-2021 Healthy Male Subjects Subjects With Haemophilia A B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Body weight 50 100 kg , inclusive Body mass index ( BMI ) 18.0 kg/m2 25.0 kg/m2 , inclusive For haemophilia subject : Diagnosed severe haemophilia A B Known suspect hypersensitivity trial product ( ) relate product Surgery plan occur trial Any major and/or orthopaedic surgery within 30 day prior trial product administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>